In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
News|Articles|October 30, 2026
FDA Roundup: Oncology Approvals, Submissions, and Designations in October 2026
Fact checked by: Sabrina Serani
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
Advertisement
Advertisement
October brought 7 FDA approvals and label expansions across solid tumors and hematologic malignancies, along with 4 notable regulatory submissions and acceptances and a breakthrough device designation for a multicancer early detection test.
Related to this article
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.
New Name, Same Connection to Care
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Advertisement
Advertisement